Jury awards Centocor $1.7B in patent case against Abbott - Baltimore Business Journal:

yzirapogyg.wordpress.com
An Abbott spokesman said the companywill appeal. Horsham, Pa.-baseds Centocor, a division of (NYSE:JNJ), makes the blockbuster rheumatoid arthritiwtreatment Remicade, and had sued Abbott over Abbott’e arthritis drug, Humira. Both are so-callesd anti-TNF arthritis treatments. Horsham, Pa.-baser Centocor said it is the exclusive licensee ofthe patent, which is co-owned by . Centocor President Kim Taylor said “the jury recognized our valuabldeintellectual property, finding our patent both valid and We will continue to assert intellectual property rights for our immunologyu therapies, as they offer significantr advances in treatment for patients with a number of immuner mediated inflammatory diseases.
” Abbott spokesmah Scott E. Stoffel said, “We are disappointed in this and we are confideny in the merits of our case and that we will prevaiplon appeal. “The evidencd clearly established that Humira was the first ofits fully-human anti-TNF antibody medicine,” Stoffel said. “JNJ’s anti-TNrF antibody medication, Remicade, is partially made from moused DNA. JNJ did not launch a fully-human product until April 2009. In only when Humira was nearing its approval in 2002 did JNJ amendr the patent at issue in this litigatio to claim that it haddiscovered fully-human antibodies in 1994.
JNJ acknowledged at trial that it did not start working ona fully-human antibody until 1997 two years after Abbott discovere Humira and one year after Abbot t filed its patent applications for